WO2008075162A3 - Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction - Google Patents

Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction Download PDF

Info

Publication number
WO2008075162A3
WO2008075162A3 PCT/IB2007/003884 IB2007003884W WO2008075162A3 WO 2008075162 A3 WO2008075162 A3 WO 2008075162A3 IB 2007003884 W IB2007003884 W IB 2007003884W WO 2008075162 A3 WO2008075162 A3 WO 2008075162A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
selective
sexual dysfunction
female sexual
receptor antagonists
Prior art date
Application number
PCT/IB2007/003884
Other languages
French (fr)
Other versions
WO2008075162A2 (en
Inventor
Vivienne Margaret Jackson
Christopher Peter Wayman
Original Assignee
Pfizer Ltd
Vivienne Margaret Jackson
Christopher Peter Wayman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, Vivienne Margaret Jackson, Christopher Peter Wayman filed Critical Pfizer Ltd
Publication of WO2008075162A2 publication Critical patent/WO2008075162A2/en
Publication of WO2008075162A3 publication Critical patent/WO2008075162A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Abstract

The invention relates to methods of treatment of female sexual dysfunction with a selective antagonist of mu opioid receptors. Combination treatments with other classes of agent are also disclosed.
PCT/IB2007/003884 2006-12-15 2007-12-03 Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction WO2008075162A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87019306P 2006-12-15 2006-12-15
US60/870,193 2006-12-15

Publications (2)

Publication Number Publication Date
WO2008075162A2 WO2008075162A2 (en) 2008-06-26
WO2008075162A3 true WO2008075162A3 (en) 2008-10-23

Family

ID=39387090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003884 WO2008075162A2 (en) 2006-12-15 2007-12-03 Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction

Country Status (4)

Country Link
JP (1) JP2008150371A (en)
AR (1) AR064368A1 (en)
TW (1) TW200833338A (en)
WO (1) WO2008075162A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013007566A2 (en) 2010-09-28 2016-08-02 Panacea Biotec Ltd new bicyclic compounds
AU2012240388A1 (en) * 2011-04-04 2013-10-24 S1 Biopharma, Inc. Treatment regimens
EA201590349A1 (en) 2012-08-06 2015-07-30 С1 Биофарма, Инк. TREATMENT MODES
RU2701861C1 (en) 2013-11-20 2019-10-02 Санва Кагаку Кенкюсо Ко., Лтд. New derivative of 3-azabicyclo[3.1.0]hexane and use thereof for medical purposes
CA2985327A1 (en) 2015-05-20 2016-11-24 Sanwa Kagaku Kenkyusho Co., Ltd. Crystal of salt of 3-azabicyclo[3.1.0]hexane derivative and pharmaceutical use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035622A1 (en) * 2001-10-22 2003-05-01 Pfizer Products Inc. 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2005037790A1 (en) * 2003-10-16 2005-04-28 Pfizer Products Inc. Preparation of 3-azabicyclo [3.1.0] hexane derivatives
US20050203123A1 (en) * 2004-03-11 2005-09-15 Adolor Corporation Substituted piperidine compounds and methods of their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035622A1 (en) * 2001-10-22 2003-05-01 Pfizer Products Inc. 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20040254208A1 (en) * 2003-04-29 2004-12-16 Eckard Weber Compositions for affecting weight loss
WO2005037790A1 (en) * 2003-10-16 2005-04-28 Pfizer Products Inc. Preparation of 3-azabicyclo [3.1.0] hexane derivatives
US20050203123A1 (en) * 2004-03-11 2005-09-15 Adolor Corporation Substituted piperidine compounds and methods of their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MILLS RICHARD H ET AL: "Estrogen-induced mu-opioid receptor internalization in the medial preoptic nucleus is mediated via neuropeptide Y-Y1 receptor activation in the arcuate nucleus of female rats.", THE JOURNAL OF NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE 28 JAN 2004, vol. 24, no. 4, 28 January 2004 (2004-01-28), pages 947 - 955, XP002481373, ISSN: 1529-2401 *
SINCHAK K ET AL: "Medial preoptic area delta-opioid receptors inhibit lordosis", BEHAVIOURAL BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 155, no. 2, 6 December 2004 (2004-12-06), pages 301 - 306, XP004567912, ISSN: 0166-4328 *
SINCHAK KEVIN ET AL: "Progesterone blockade of estrogen activation of mu-opioid receptors regulates reproductive behavior", JOURNAL OF NEUROSCIENCE, vol. 21, no. 15, 1 August 2001 (2001-08-01), pages 5723 - 5729, XP002481374, ISSN: 0270-6474 *

Also Published As

Publication number Publication date
WO2008075162A2 (en) 2008-06-26
TW200833338A (en) 2008-08-16
JP2008150371A (en) 2008-07-03
AR064368A1 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
WO2007003411A3 (en) Kinin antagonists for treating bladder dysfunction
WO2008042611A3 (en) Method of using il6 antagonists with mitoxantrone for prostate cancer
SI2001876T1 (en) 8-azabicycloy3.2.1 octane compounds as mu opioid receptor antagonists
HK1136302A1 (en) Progesterone receptor antagonists
WO2008030367A3 (en) Selective myostatin inhibitors
MX2007008756A (en) Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction.
HK1146822A1 (en) Kappa selective opioid receptor antagonist kappa
WO2011020030A3 (en) Methods and compositions to prevent addiction
IL199015A0 (en) Quinuclidinol derivatives as muscarinic receptor antagonists
WO2007119214A3 (en) Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
WO2007141284A3 (en) Treatment of gastrointestinal disorders with cgrp antagonists
BRPI0815797A2 (en) 8-Azabicyclo [3.2.1] octyl-2-hydroxybanzamide compounds as mu opioid receptor antagonists
WO2008002946A3 (en) Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist
CO6341547A2 (en) USE OF OPIOID ANTAGONISTS FOR THE TREATMENT OF URINARY RETENTION
WO2008075162A3 (en) Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
SI2238110T1 (en) 5.6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as antagonists for urotensine ii receptors
ZA201008538B (en) Treating psychological conditions using muscarinic receptor m1 antagonists
IL205949A0 (en) 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
HK1135110A1 (en) Nk1 receptor antagonist composition nk1
ZA200904479B (en) Nitroderivatives as angiotensin II receptor antagonists
WO2007115975A3 (en) USE OF kappa OPIOID RECEPTOR ANTAGONIST-CONTAINING COMPOSITIONS FOR THE TREATMENT OF DISSOCIATIVE DISORDERS
WO2006106358A3 (en) Use of nk-3 receptor antagonists for the treatment of nausea and vomiting
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
HK1163571A1 (en) Selective histamine h4 receptor antagonists for the treatment of vestibular disorders h4
WO2008110697A3 (en) Use of a compound antagonist to the nk2 receptors of a neurokinine for the preparation of drugs useful for preventing and treating sexual dysfunction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07859019

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07859019

Country of ref document: EP

Kind code of ref document: A2